Literature DB >> 12078762

Personal experience in lung cancer sleeve lobectomy and sleeve pneumonectomy.

Maurizio Mezzetti1, Tiziana Panigalli, Luigi Giuliani, Federico Raveglia, Fabio Lo Giudice, Stefano Meda.   

Abstract

BACKGROUND: Sleeve lobectomy (SL) and tracheal sleeve pneumonectomy (TSP) represent valuable alternative techniques to standard resections in the treatment of benign and malignant conditions of the airway and allow preservation of lung parenchyma.
METHODS: Eighty-three sleeve lobectomies and 27 tracheal sleeve pneumonectomies have been performed for nonsmall cell lung cancer in the thoracic department of the University of Milan from 1979 to 1999. There were 46 upper right lobectomies, 11 upper and middle lobectomies, 18 upper left lobectomies, 8 lower left lobectomies, and 27 right pneumonectomies.
RESULTS: Mortality rate was 3.6% in SL and 7.4% in TSP. Complications were 10.8% of all SLs and 15% of all TSPs. The overall 5-year survival rate was 43% for SL and 20% for TSP; the 10-year survival rate was 34% and 14%, respectively. There was a highly significant difference in survival between patients with N0 and N1-N2 disease.
CONCLUSIONS: Sleeve lobectomy is an appropriate surgical procedure and an alternative to pneumonectomy in patients with limited respiratory reserve whenever the situation permits. Trachael sleeve pneumonectomy is associated with more complications and poor survival.

Entities:  

Mesh:

Year:  2002        PMID: 12078762     DOI: 10.1016/s0003-4975(02)03524-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival.

Authors:  Mark F Berry; Mathias Worni; Xiaofei Wang; David H Harpole; Thomas A D'Amico; Mark W Onaitis
Journal:  Ann Thorac Surg       Date:  2013-11-06       Impact factor: 4.330

2.  Cost analysis of pulmonary lobectomy procedure: comparison of stapler versus precision dissection and sealant.

Authors:  Andrea Droghetti; Giuseppe Marulli; Jacopo Vannucci; Michele Giovanardi; Maria Caterina Bottoli; Mark Ragusa; Giovanni Muriana
Journal:  Clinicoecon Outcomes Res       Date:  2017-04-03

3.  Standard versus extended pneumonectomy for lung cancer: what really matters?

Authors:  Dragan Subotic; Milan Savic; Nikola Atanasijadis; Milan Gajic; Jelena Stojsic; Marko Popovic; Vladimir Milenkovic; Zeljko Garabinovic
Journal:  World J Surg Oncol       Date:  2014-08-03       Impact factor: 2.754

4.  Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells.

Authors:  Zhiyuan Ma; Aiqiang Dong; Minjian Kong; Jianfang Qian
Journal:  Cell Mol Biol Lett       Date:  2007-06-24       Impact factor: 5.787

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.